Physician profile
Benjamin Scoll
NPI 1174762116
$784.44
in general payments reported to CMS, 2019-2025
13 companies · $71.93 in 2025
The $71.93 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $84.20 · 2021: $60.89 · 2022: $150 · 2023: $221 · 2024: $41.28 · 2025: $71.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.30 |
| Education | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $130.00 | 2023 | Erleada |
| Boston Scientific Corporation | $104.18 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $91.20 | 2022 | |
| Pfizer INC. | $84.58 | 2019-2022 | |
| Dentsply Ih INC. | $82.33 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $71.93 | 2025 | |
| Abbvie INC. | $53.92 | 2019-2023 | Botox |
| Tolmar, INC. | $48.69 | 2023 | |
| Photocure INC | $26.23 | 2019 | |
| Sumitomo Pharma America, INC. | $26.17 | 2023 | Gemtesa |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.39 | 2024 | Adstiladrin |
| Axonics, INC. | $17.89 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Scoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.